针对肠炎肥胖患者，司美格鲁肽比其他减肥药更有效！

Core Viewpoint - The article discusses the effectiveness and safety of Semaglutide in weight loss for patients with Inflammatory Bowel Disease (IBD), highlighting its comparable results to non-IBD patients and its advantages over other anti-obesity medications [4][7][10]. Group 1: Relationship Between Obesity and IBD - There is a complex relationship between obesity and IBD, where obesity may increase the incidence and complications of IBD [5]. - An estimated 41% of the U.S. population is obese, with nearly 1 in 100 diagnosed with IBD. Among IBD patients, 15% to 40% are obese, and 20% to 40% are overweight [6]. - Obesity, particularly visceral obesity, is a chronic inflammatory state of white adipose tissue, which may be a risk factor for developing IBD. Obese IBD patients have a higher risk of complications compared to non-obese IBD patients [6]. Group 2: Efficacy of Semaglutide - Semaglutide has shown significant and sustained weight loss effects in the general population, and a study indicates that IBD patients experience similar weight loss to non-IBD patients [7]. - A large study published in March 2021 found that individuals taking Semaglutide lost an average of 14.9% of their body weight over 68 weeks [7]. - A retrospective cohort study compared 47,424 obese IBD patients with 21,019 obese non-IBD patients, assessing overall weight changes after starting Semaglutide [9]. Group 3: Study Findings - The study matched 150 obese IBD patients with 150 obese non-IBD patients, with follow-up periods of 18 months for IBD and 19.4 months for non-IBD [9]. - The average total body weight (TBW) change for IBD and non-IBD groups was similar, with IBD patients losing an average of 16 pounds and non-IBD patients losing 15 pounds over 6 to 12 months [9]. - Semaglutide resulted in greater TBW loss compared to Liraglutide (-13 pounds vs -19 pounds) but less than Tirzepatide (-18 pounds vs -26 pounds) [10]. Group 4: Safety and Hospitalization Risks - There were no significant differences in the risk of emergency visits or hospitalization between the Semaglutide group and the non-Semaglutide group [10]. - The risk of hospitalization for any reason was significantly lower in the IBD Semaglutide group [10]. - The study aims to alleviate concerns regarding the efficacy and safety of Semaglutide for IBD patients [11].